Autoimmune specialist Galapagos NV (Mechelen, Belgium) has priced its 3,750,000 American Depository Shares (ADSs) in an follow-on offering led by Morgan Stanley at $90 per ADS.
In December 2016, US biotech company Ionis Pharmaceuticals’ drug Spinraza received regulatory approval in the US. No doubt: the antisense technology behind Spinraza could be the next big thing
Irish Allergan and Swiss Novartis have agreed to start a proof-of-concept study of a combination of their NASH candidates cenicriviroc (Allergan) and FXR agonist LJN452 (Novartis).
sphingotec GmbH and bestbion dx GmbH have signed an agreement to market sphingotec’s innovative sepsis and congestive heart failure test (sphingotest bio-ADM) and acute kidney function monitoring assay (sphingotest penKid) in Germany and Austria.
German and Swedish researchers have presented a strategy to predict and improve chemotherapy outcomes in patients with acute myelogenous leukaemia (AML). Currently, the five-year overall survival rate of AML patients treated with cytarabine (ara-C) standard chemotherapy ranges from 20-70%.
Police investigators today begin searches for perpetrators with conventional DNA profiling – comparing a genetic signature from sperm or hair left at a crime scene with a database of identified offenders. But that doesn’t finger culprits who have never been registered. A growing technology called DNA phenotyping’ is now aimed at interpreting genomic clues about a suspect’s possible external appearance. The science behind it is new, and investigators have to navigate the statistical uncertainties – as well as ethical and legal questions – the technology is raising all over Europe.
https://european-biotechnology.com/wp-content/uploads/2024/04/2017spring-forensic-evidence.jpg6751200Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-04-11 16:41:372017-04-11 16:41:37Phenotyping: The hidden mugshot in a culprit’s DNA
Hansa Medical, Lund-based developer of novel immunomodulatory enzymes, has recruited Sam Agus as Chief Medical Officer. Agus joins from H. Lundbeck AS, where he was Chief Specialist, Medical Affairs Neurology.
https://european-biotechnology.com/wp-content/uploads/2024/04/sam-agus.jpg473420h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2017-04-11 15:06:102017-04-11 15:06:10Hansa Medical: Taking charge of medical affairs
e-Therapeutics: Newly in charge
AppointmentsGalapagos raises US$338m
Latest NewsAutoimmune specialist Galapagos NV (Mechelen, Belgium) has priced its 3,750,000 American Depository Shares (ADSs) in an follow-on offering led by Morgan Stanley at $90 per ADS.
A potentially game-changing technology
OpinionAllergan and Novartis combine NASH candidates
Latest NewsIrish Allergan and Swiss Novartis have agreed to start a proof-of-concept study of a combination of their NASH candidates cenicriviroc (Allergan) and FXR agonist LJN452 (Novartis).
Domainex: Navigating the growth
Appointmentsbestbion dx to market sphingotec’s predictive biomarkers
Latest Newssphingotec GmbH and bestbion dx GmbH have signed an agreement to market sphingotec’s innovative sepsis and congestive heart failure test (sphingotest bio-ADM) and acute kidney function monitoring assay (sphingotest penKid) in Germany and Austria.
Blood cancer: Boosting chemotherapy effects
BackgroundGalenica exercises over-allotment option
Latest NewsFollowing its CHF1.901bn IPO at SIX Swiss Exchange on 7 April, Galenica Santé has announced full excercise of the over-allotment option worth CHF248m.
Phenotyping: The hidden mugshot in a culprit’s DNA
BackgroundHansa Medical: Taking charge of medical affairs
Appointments